Medpace
- Market cap
- 16.87B
- P/E (TTM)i
- 35.50
- P/Bi
- 38.87
- EPSi
- 15.28
- Div yieldi
- 0.00%
- 52W posi
- 76%
Anonymous reader poll. Unscientific, not investment advice.
Shares of Medpace closed at 604.25, up 0.22%. At current prices, the business is worth about 16.87B, the #1015 most valuable US-listed company we track. Trading at a P/E of 36.67, the stock is 12% above its own five-year norm of 32.84. Wall Street's 9-analyst consensus lands on Hold, with a price target averaging 629.86 (+4% from here). The shares sit 76% of the way up their 52-week range of 373.00 to 677.90.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 2 months.
- Recent price momentum is +12.1% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 6.0% of float.
- Analyst tilt is Hold.
- Price is below its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation D+
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 36.5x | Better than 20% |
| Forward P/E | 33.6x | Better than 16% |
| Price / Sales | 6.3x | Better than 21% |
| P/E vs own 5-yr range | 76th pctl | Better than 32% |
Growth A
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 20.1% | Better than 84% |
| Net income CAGR (3Y) | 22.5% | Better than 76% |
| Free cash flow CAGR (3Y) | 24.8% | Better than 70% |
Profitability A-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 30.1% | Better than 27% |
| Operating margin | 21.1% | Better than 68% |
| Net margin | 17.8% | Better than 70% |
| Return on equity | 70.2% | Better than 93% |
| Return on invested capital | 59.2% | Better than 99% |
Momentum A-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 13.6% | Better than 81% |
| 6-month return | 22.0% | Better than 73% |
| 12-month return (ex latest month) | 11.5% | Better than 46% |
| Distance below 52-week high | 8.5% | Better than 81% |
Financial Health A-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 0.7x | Better than 11% |
| Debt to assets | 5.8% | Better than 85% |
| Interest coverage | 80.6x | Better than 92% |
| Free cash flow / net income | 151.1% | Better than 73% |
Analyst View D-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 22.2% | Better than 9% |
| Upside to average target | 1.5% | Better than 6% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 602.90
- Open
- 600.00
- Day range
- 596.08 - 615.63
- Avg price
- 605.49
- Volume
- 207.57K
- Turnover
- 125.68M
- Turnover ratei
- 0.92%
- Volume ratioi
- 0.74
- Amplitudei
- 3.24%
- 52-week rangei
- 373.00 - 677.90
Valuation
- P/Ei
- 39.55
- P/E (TTM)i
- 35.50
- P/Bi
- 38.87
- EPSi
- 15.28
- Book value / shi
- 15.54
- Net profit
- 426.49M
- Net assets
- 433.86M
Share structure
- Market cap
- 16.87B
- Float capi
- 13.69B
- Shares out
- 27.91M
- Float sharesi
- 22.66M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2016-08-11
10.9% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+5.07M net over the window
Short interest
- Shares short
- 1.69M
- % of floati
- 6.04%
- Days to coveri
- 8.82
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Medpace (MEDP)?
Medpace last traded at 604.25. The quote on this page refreshes every few seconds while US markets are open.
What is Medpace's market cap?
About 16.87B.
What is the P/E ratio of Medpace?
The trailing twelve-month P/E is 35.50, above its own 5-year average of 32.84 — toward the top of its historical range (76.46% percentile). See the Valuation tab for the full history.
Does Medpace pay a dividend?
Medpace does not currently pay a regular dividend.
Is Medpace a buy according to analysts?
The consensus of 9 analysts is a Hold rating, with an average 12-month price target of 629.86, which implies 4.2% upside from the current price. This is not investment advice.
What is Medpace's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Medpace a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-10-08 03:14:43 · For reference only, not investment advice and not tailored to your situation.